ZynexZYXI
ZYXI
About: Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.
Employees: 1,101
0
Funds holding %
of 7,139 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
1.57% less ownership
Funds ownership: 26.93% [Q3] → 25.36% (-1.57%) [Q4]
4% less funds holding
Funds holding: 100 [Q3] → 96 (-4) [Q4]
7% less capital invested
Capital invested by funds: $69.8M [Q3] → $64.7M (-$5.04M) [Q4]
21% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 14
29% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 35
67% less call options, than puts
Call options by funds: $25K | Put options by funds: $76K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$17
136%
upside
Avg. target
$17
136%
upside
High target
$17
136%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Yi Chen 42% 1-year accuracy 67 / 161 met price target | 136%upside $17 | Buy Reiterated | 6 Dec 2024 |
Financial journalist opinion
Positive
Proactive Investors
3 weeks ago
Zynex eyes FDA submission for NiCO oximeter as it expands portfolio of innovative medical devices
Zynex Inc (NASDAQ:ZYXI) continues to expand its portfolio of innovative, non-invasive medical devices targeting pain management, rehabilitation, and pain monitoring. The company's flagship NexWave product is a multi-modality electrotherapy device that combines various therapeutic modalities to provide effective pain relief.
Positive
Proactive Investors
2 months ago
Zynex partners with VA to offer pain management solutions for veterans
Zynex Inc (NASDAQ:ZYXI) has announced a new partnership with Veterans Affairs Medical Centers (VAMCs) across the United States, a significant opportunity to expand the reach of its noninvasive medical devices for pain management and rehabilitation. This collaboration provides an opportunity to expand sales of Zynex's pain management solutions within the largest healthcare network in the US, which serves over 9 million enrolled veterans annually and accounts for more than $112 billion in annual healthcare spending.
Neutral
PRNewsWire
2 months ago
Zynex Announces Partnership To Conduct Business with Veterans Affairs (VA) Medical Centers, the Largest Healthcare Network in the United States
VA Spending on Hospital and Medical Care Exceeds $112 Billion Annually ENGLEWOOD, Colo. , Dec. 17, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced a new partnership to conduct business with Veterans Affairs Medical Centers (VAMCs) across the United States.
Positive
Proactive Investors
2 months ago
Zynex CEO outlines plans for 2025 after revenue milestone – ICYMI
Zynex Inc (NASDAQ:ZYXI) CEO Thomas Sandgaard spoke with Proactive about the company's 2024 achievements and plans for 2025. Zynex reached $200 million in revenue while staying profitable, thanks to employee dedication and innovative pain management products like braces and cold therapy devices.
Positive
Proactive Investors
2 months ago
Zynex study highlights precision of laser-based pulse oximeter in reducing racial bias
Zynex Inc (NASDAQ:ZYXI) announced findings from study demonstrating that its NiCO laser pulse oximeter eliminates the impact of skin pigmentation on blood oxygenation (SpO2) measurements. The University of California, San Francisco-led study compared Zynex's NiCO device to conventional LED-based pulse oximeters.
Neutral
PRNewsWire
2 months ago
Zynex UCSF Study Results Demonstrate Laser Technology Benefits in Resolving Racial Bias of Current LED Pulse Oximeters
ENGLEWOOD, Colo. , Dec. 12, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced highlights from a recent study comparing its NiCO™ laser pulse oximeter to conventional LED pulse oximeters for the effects of skin pigmentation on SpO2 measurements conducted by the University of California, San Francisco (UCSF) Hypoxia Lab.
Positive
Zacks Investment Research
2 months ago
ZYXI Stock Gains on the Completion of NiCO's Clinical Verification Trial
Zynex announces the completion of the clinical verification trial of its NiCO pulse oximeter.
Neutral
PRNewsWire
2 months ago
Zynex Announces Completion of Its Laser Pulse Oximetry Trial
ENGLEWOOD, Colo. , Dec. 5, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that it has completed its clinical verification trial for their NiCO™ pulse oximeter overseen by anesthesiologist Dr. David MacLeod at Duke University.
Positive
Proactive Investors
2 months ago
Zynex joins Open Oximetry Project as it advances innovative NiCO pulse oximeter
Zynex Inc (NASDAQ:ZYXI) has announced its membership in the Collaborative Community of the Open Oximetry Project as an industry member. This initiative, led by the University of California, San Francisco's Center for Health Equity in Surgery and Anesthesia, aims to enhance the safety and accuracy of pulse oximeters across diverse populations.
Neutral
PRNewsWire
2 months ago
Zynex Announces Open Oximetry Project Membership
ENGLEWOOD, Colo. , Dec. 3, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced its membership in the Collaborative Community of the independently led Open Oximetry Project as an industry member.
Charts implemented using Lightweight Charts™